Active Ingredient(s): Risdiplam
FDA Approved: * August 7, 2020
Pharm Company: * GENENTECH INC
Category: Genetic Disorders

Risdiplam, sold under the brand name Evrysdi, is a medication used to treat spinal muscular atrophy (SMA)[4][5] and the first oral medication approved to treat this disease.[4][5] Risdiplam is a survival of motor neuron 2-directed RNA splicing modifier.[4][3][6] In clinical trials, the most common adverse events included fever, diarrhea, rash, ulcers of the mouth area, joint pain (a... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Evrysdi .75 mg/ml Oral Powder, for Solution
NDC: 50242-175
Genentech Inc.